NextHen
Eytan Meisels is an accomplished regulatory affairs executive with extensive experience in the biochemistry and diagnostics industries. Currently serving as Vice President of Regulatory Affairs at HUMIN and its subsidiaries since February 2020, Eytan has previously held prominent roles such as VP Quality Assurance & Regulatory Affairs at Samsara Vision and VP, Regulatory Affairs at Abbott Diagnostics, focusing on infectious diseases in emerging markets. Eytan's career spans various leadership positions in regulatory and quality assurance across multiple companies, including Alere and Orgenics. Eytan holds a Ph.D. in Biochemistry from the Weizmann Institute of Science and has completed postdoctoral fellowships at both the Weizmann Institute of Science and The Johns Hopkins University School of Medicine, complemented by extensive education in biochemistry and chemistry.
This person is not in any teams
This person is not in any offices
NextHen
NextHen is led by industry experts and operates based on a joint venture with the Agriculture Research Organization (ARO) - the Ministry of Agriculture of the State of Israel. NextHen specializes in identification through to expression of advantageous phenotypes (traits) of both broilers and layers in the poultry industry. Its flagship project is providing a sustainable, cost-saving way to end the culling of male chicks, by enabling the laying of eggs from which only non-GMO females hatch - the only viable method to end the slaughter of 7 billion chicks each year. Breeders can now benefit from an increase in production volume and efficiency by freeing up significant incubation space, without any changes to the manufacturing process or additional machinery; Significant cost reduction related to the egg sorting process (human and machine); And accelerate production process by reducing the volume of eggs transferred into incubators.